title: Interleukin-17 and innate immunity in infections and chronic inflammation.
abstract: Interleukin 17 (IL-17) includes several cytokines among which IL-17A is considered as one of the major pro-inflammatory cytokine being central to the innate and adaptive immune responses. IL-17 is produced by unconventional T cells, members of innate lymphoid cells (ILCs), mast cells, as well as typical innate immune cells, such as neutrophils and macrophages located in the epithelial barriers and characterised by a rapid response to infectious agents by recruiting neutrophils as first line of defence and inducing the production of antimicrobial peptides. Th17 responses appear pivotal in chronic and acute infections by bacteria, parasites, and fungi, as well as in autoimmune and chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, and psoriatic arthritis. The data discussed in this review cumulatively indicate that innate-derived IL-17 constitutes a major element in the altered immune response against self antigens or the perpetuation of inflammation, particularly at mucosal sites. New drugs targeting the IL17 pathway include brodalumab, ixekizumab, and secukinumab and their use in psoriatic disease is expected to dramatically impact our approach to this systemic condition.
authors.affiliation: Division of Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy.
authors.forename: Natasa
authors.initials: N
authors.lastname: Isailovic
authors.affiliation: Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Rozzano, Italy.
authors.forename: Kenji
authors.initials: K
authors.lastname: Daigo
authors.affiliation: Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Rozzano, Italy; Humanitas University, Rozzano, Italy. Electronic address: alberto.mantovani@humanitasresearch.it.
authors.forename: Alberto
authors.initials: A
authors.lastname: Mantovani
authors.affiliation: Division of Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy; BIOMETRA Department, University of Milan, Milan, Italy. Electronic address: carlo.selmi@humanitas.it.
authors.forename: Carlo
authors.initials: C
authors.lastname: Selmi
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000276:immunology; D015551:Autoimmunity / Q000276:immunology*; D001424:Bacterial Infections / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate / Q000276:immunology; D007239:Infections / Q000276:immunology*; D007249:Inflammation / Q000276:immunology*; D020381:Interleukin-17 / Q000037:antagonists & inhibitors / Q000276:immunology*; D008264:Macrophages / Q000276:immunology; D009181:Mycoses / Q000276:immunology; D009504:Neutrophils / Q000276:immunology; D010272:Parasitic Diseases / Q000276:immunology; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology; D014777:Virus Diseases / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D020381:Interleukin-17; C571216:brodalumab; C549079:ixekizumab; C555450:secukinumab
keywords: Brodalumab; Infection; Ixekizumab; Psoriasis; Psoriatic arthritis; Secukinumab